Tackling antimicrobial resistance (AMR) through antimicrobial stewardship (AMS) interventions is a key objective within the World Health Organization (WHO)'s Global Action on AMR. We outline the reasons why global collaborations for AMS are needed. We provide examples of global collaborations, and we offer considerations when starting on a global health journey focused on AMS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127241 | PMC |
| http://dx.doi.org/10.1017/ash.2023.122 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What Can We Learn From Qualitative Impact Evaluations About the Effectiveness of Lobby and Advocacy? A Meta-Evaluation of Dutch aid Programmes and Assessment Tool.
Eval Rev
January 2025
Global Development Network, Lanzhou University and Director of Evaluation, New Delhi, India.
Official development agencies are increasingly supporting civil society lobby and advocacy (L&A) to address poverty and human rights. However, there are challenges in evaluating L&A. As programme objectives are often to change policies or practices in a single institution like a Government Ministry, L&A programmes are often not amenable to large-n impact evaluation methods.
View Article and Find Full Text PDFGlobal research trends and emerging hotspots in nano-drug delivery systems for lung cancer: a comprehensive bibliometric analysis (1998-2024).
Discov Oncol
January 2025
Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, 400010, China.
Purpose: Nano-drug delivery systems (NDDS) have become a promising alternative and adjunctive strategy for lung cancer (LC) treatment. However, comprehensive bibliometric analyses examining global research efforts on NDDS in LC are scarce. This study aims to fill this gap by identifying key research trends, emerging hotspots, and collaboration networks within the field of NDDS and LC.
View Article and Find Full Text PDFCAR/CSACI Practice Guidance for Contrast Media Hypersensitivity.
Can Assoc Radiol J
January 2025
Department of Radiology, Dalhousie University, Halifax, NS, Canada.
Contrast media, including iodinated contrast media and gadolinium-based contrast agents, are commonly administered pharmaceuticals with excellent safety profiles. However, a minority of the population may experience a hypersensitivity reaction following intravenous administration. Hypersensitivity reactions can be immediate or delayed, and range from mild, such as urticaria, to severe, including anaphylaxis.
View Article and Find Full Text PDFImmunogenicity and safety of HepE Hecolin® in chronic hepatitis B patients at clinically stable stage: An open-label study in China.
Hum Vaccin Immunother
December 2025
Academy of Preventive Medicine, Shandong University, Jinan, China.
Acute hepatitis E infection could induce severe outcomes among chronic hepatitis B (CHB) patients. Between 2016 and 2017, an open-label study was conducted to evaluate the immunogenicity and safety of hepatitis E vaccine (HepE) in CHB patients, using healthy adults as parallel controls in China. Eligible participants who were aged ≥30 y were enrolled in the study.
View Article and Find Full Text PDFCAR-T cell therapy in developing countries: how long should we wait?
J Immunother Cancer
December 2024
Center for Regenerative Medicine, Kathmandu, Nepal
Low- and middle-income countries (LMICs) face a significant burden of cancer prevalence and incidence. However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatments. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising outcomes in certain terminally ill patients with cancer, yet access to this treatment remains limited in LMICs, including Nepal.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!